Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer

The three major conventional treatments: surgery, chemotherapy, and radiation therapy, have been commonly performed for lung cancer. However, lung cancer is still the leading cause of cancer-related mortality. Immunotherapy has recently emerged as a very effective new treatment modality, and there i...

Full description

Saved in:
Bibliographic Details
Published in:Life (Basel, Switzerland) Switzerland), 2021-09, Vol.11 (10), p.1029
Main Authors: Kinoshita, Tomonari, Terai, Hideki, Yaguchi, Tomonori
Format: Article
Language:English
Subjects:
Antigens
Cancer immunotherapy
Cancer therapies
Cancer vaccines
Chemotherapy
Clinical trials
Cytokines
Cytotoxicity
immune checkpoint inhibitor
Immune checkpoint inhibitors
Immune system
Immunotherapy
Inhibitors
Lung cancer
Medical prognosis
Melanoma
Mutation
Platinum
Radiation
Radiation therapy
Review
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The three major conventional treatments: surgery, chemotherapy, and radiation therapy, have been commonly performed for lung cancer. However, lung cancer is still the leading cause of cancer-related mortality. Immunotherapy has recently emerged as a very effective new treatment modality, and there is now growing enthusiasm for cancer immunotherapy worldwide. However, the results of clinical studies using immunotherapy are not always favorable. Understanding the steps involved in the recognition and eradication of cancer cells by the immune system seems essential to understanding why past immunotherapies have failed and how current therapies can be optimally utilized. In addition, the combination of immunotherapies, such as cancer vaccines and immune checkpoint inhibitors, as well as the combination of these therapies with three conventional therapies, may pave the way for personalized immunotherapy. In this review, we summarize the results of immunotherapies used in phase III clinical trials, including immune checkpoint inhibitors, and discuss the future prospects of immunotherapies in lung cancer treatment.
ISSN:2075-1729
2075-1729
DOI:10.3390/life11101029